XML 44 R28.htm IDEA: XBRL DOCUMENT

Subsequent event	12 Months Ended
Subsequent event	Dec. 31, 2025
Subsequent Events [Abstract]
Subsequent event	Note 19: Subsequent Event Optune Pax Approval On February 11, 2026, the U.S. Food and Drug Administration approved Optune Pax for for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel. As a result of this approval, the Company expects to expense approximately $43,406 related to the vesting of 901,284 PSUs granted in March 2020 to an executive officer that are not expected to be distributed. See Note 15 above.